Our founders are building beyond the pre-defined edges of human health. Through the convergence of AI, technology, and biology, and the reimagining of healthcare, we’re the first call for bold entrepreneurs pushing boundaries and leading the way towards better care for all.
From life sciences to care delivery, spanning seed financing through IPO, we’re partnering with a new generation of determined, multidisciplinary entrepreneurs across the entire company‑building journey. Together we are building iconic companies that are radically transforming how we diagnose, treat, and manage disease, while building the healthcare system of tomorrow–a system of Enduring Health (™). Together, we are building the future. The Future is Health.
Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health.
Jonathan Lim, chairman and CEO of Erasca, joins Jorge Conde, general partner at a16z. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making.
Today, we are thrilled to announce our investment in Alchemy as they work to better connect our life sciences and healthcare delivery systems and solve these supply-demand mismatches in the pharmaceutical value chain. Alchemy has emerged to empower the long tail of independent providers with the physical, clinical, and digital infrastructure they need to fully serve their patient communities effectively, and profitably.
If these modalities have proven to be so effective (in some cases, even curative) against cancer, is there a role for them outside oncology, in the treatment of chronic diseases that might also be driven by a population of bad-actor cells? Arda Therapeutics is building upon exactly this bold hypothesis.
Vijay Pande, general partner, and Daisy Wolf, investing partner, join host Steph Smith on this crossover episode of the a16z podcast.
Marta Bralic Kerns, founder and CEO of Pomelo Care, joins Will Shrank, MD, a16z Bio + Health venture partner. Together, they talk about the innovator’s dilemma with building in the Medicaid space
Nikita Singareddy, cofounder and CEO of Fortuna Health, joins Will Shrank, MD, a16z Bio + Health venture partner. This is the second episode in our Medicaid Matters series.
GCTx is flipping the entire iPSC differentiation paradigm on its head. Rather than manually iterating through a limited set of differentiation protocols, the Human TFome technology platform instead deploys large-scale combinatorial screening to discover new hypotheses and new protocols that are as-yet unknown to even the best biologists.
Over the next three episodes, we’re going to talk about why Medicaid matters, and the potential for technology to make it easier for enrollees to access and utilize the program. Our first guest is Mark Smith, MD, Clinical Professor of Medicine at UCSF.
Ambience cofounder Nikhil Buduma discusses how to build vertical applications with AI models, including in health care, and why tech expertise isn't enough.
Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast.
Casey Means, MD, a Stanford-trained physician, cofounder of Levels, and author of the new book Good Energy, joins Vijay Pande, PhD, founding partner of a16z Bio + Health.
Half of prescribed medications are never taken, and 88% of Americans are metabolically unhealthy. Despite spending 20% of our GDP on healthcare—twice that of any other developed nation—our outcomes still lag behind. In t...
Consumers are effectively a new class of payor. And a number of opportunities exist to build solutions for those consumers (aka these new “micro payors”) to fund, navigate, and manage their healthcare purchases.
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z. This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI.
Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, PhD, general partner at a16z Bio + Health.
Whereas we historically have viewed the low adoption of software as a liability, we now view that as an asset—we don't face the same sunk cost bias that might be slowing other industries down from taking full advantage of the latest AI innovations.
Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.
Vijay Pande walks us through two decades of applying software engineering and AI to biotech and health care — from Folding@Home through AlphaFold and more.
Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health.
In this episode, a follow-up to our episode Grand Challenges in Healthcare AI, Julie Yoo and Vijay Pande, a16z general partners, answer audience questions about AI applications in healthcare.
John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joins Jorge Conde, general partner at a16z Bio + Health.
Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health.
Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.
Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.
Recently, we invested in Function Health, a company that embodies the vision and excitement we had when writing those theses. The one piece we underestimated is the current state of latent demand among consumers for a new approach to healthcare and longevity.
This medical home is exactly what knownwell is building – and scaling. Through a hybrid virtual and in-person care model, knownwell offers both primary care as well as longitudinal specialty care, inclusive of weight management, diabetes care, medication (and side effect) management, multi-disciplinary nutritional counseling, and behavioral health services.
The most impactful way to fix healthcare is through improving the consumer experience, which has been largely ignored to date. In today’s modern world where you can order groceries, buy flight tickets, and wire money from your phone, taking care of yourself and navigating the healthcare system remains impossibly hard.
In this episode, originally recorded for the a16z Podcast, host Steph Smith interviews Pushmeet Kohli, DeepMind's VP of Research focused on AI for science. They are joined by a16z Bio + Health founding partner Vijay Pand...
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health.
Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.
There is perhaps nowhere more exciting or impactful to build such tools than in healthcare—where progress is often so constrained by human expertise. Valar Labs is taking on exactly this challenge, and bringing AI into the toolbox for better cancer care.
As Ozempic, Wegovy, Mounjaro, and Zepbound capture the healthcare spotlight, we’ve developed a series of episodes that go beyond the headlines and take you into conversations with the specialists. Our first guest is Carolyn Jasik, MD, Chief Medical Officer at Omada Health.
Vineeta Agarwala, MD, PhD, joins Luke Timmerman's The Long Run podcast on stage at the Life Science Innovation Northwest Conference.
The stakes are high. The opportunities are profound. From the creation of new medicines to bolstering national defense, this is our vision for the AI-enabled future.
Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health. Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab.
In recent years, the AI landscape has seen huge advancements, from the release of Dall-E 2 in April 2022 to the emergence of AI music and video models in early 2024. While creative tools often steal the spotlight, AlphaF...
Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.
Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.
Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.
This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.
Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.
Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.
Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
Scribe Therapeutics cofounder and CEO Ben Oakes joins a16z Bio + Health founding general partner Vijay Pande.
The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. But how can biotech teams effectively communicate to investors and partners how they will, with each round of financing, incrementally reduce the risks of discovering and developing successful new drugs?
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.
Today's episode features the cofounders of Tome Biosciences, Rahul Kakkar, CEO of Tome, and John Finn, CSO. They are joined by Jorge Conde, general partner at a16z Bio + Health.
We have long believed that AI will fundamentally reshape biotech and healthcare, positioning us at the brink of an AI-driven Industrial Revolution. But when will we see this payoff? Put more boldly, when will the majority of new drugs be designed with AI?
Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit. Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences.
AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, and co-hosts Kris Tatiossian and Olivia Webb, on this journey.
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.
Catalysts. Conveners. Connective Tissue. Bringing tech-enabled innovations to patients through ecosystem partnerships.
We’re former founders, operators, and entrepreneurs. We’re MDs, PhDs, scientists, and technologists. We bring the know-how and networks of five full operating teams and deep expertise from across our consumer, enterprise, and fintech practices to help founders find their edge.
We win as one team, and we win big.
See Full Team
Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.
